Literature DB >> 21490083

The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development.

Yoshika Takahashi1, Maiko Hasegawa-Moriyama, Takashi Sakurai, Eiichi Inada.   

Abstract

BACKGROUND: Neuroinflammation triggered by macrophage infiltration into sites of peripheral nerve injury may result in neuropathic pain. Peroxisome proliferator-activated receptor (PPAR)γ signaling regulates the properties of macrophages. However, the macrophage-mediated effects of PPARγ signaling on neuropathic pain triggered by peripheral inflammation have not been investigated.
METHODS: To evaluate the peripheral effects of PPARγ signaling on tactile allodynia, we administered the blood-brain barrier-impermeant PPARγ agonist, rosiglitazone, after partial sciatic nerve ligation (PSNL) as (1) systemic treatment during different phases of neuropathic pain development, (2) local injection to the PSNL site in the early phase, or (3) peritoneal macrophages pretreated with rosiglitazone transplanted into the PSNL site. In addition, the direct effect of rosiglitazone was evaluated in peritoneal macrophages activated with interferon-γ.
RESULTS: Systemic rosiglitazone treatment early in the course of progressive inflammation ameliorated tactile allodynia, macrophage infiltration, and production of proinflammatory mediators including cyclooxygenase-2, inducible nitric oxide synthase, and matrix metalloprotease 9 at the PSNL site. Local injection of rosiglitazone and transplantation of rosiglitazone-treated peritoneal macrophages at the ligation site significantly improved tactile allodynia. In peritoneal macrophages, rosiglitazone down-regulated interferon-γ-induced gene expression of cyclooxygenase-2 and inducible nitric oxide synthase and attenuated the chemotactic response to monocyte chemotactic protein-1. DISCUSSION: Rosiglitazone treatment in the early phase of neuropathic pain significantly alleviated the development of tactile allodynia by regulating macrophage infiltration and production of proinflammatory molecules at the inflamed site. Our results indicate that the activation of PPARγ signaling in macrophages during the early phase may suppress neuropathic pain development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490083     DOI: 10.1213/ANE.0b013e31821b220c

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  20 in total

Review 1.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

2.  PPARγ activation blocks development and reduces established neuropathic pain in rats.

Authors:  J Morgenweck; R B Griggs; R R Donahue; J E Zadina; B K Taylor
Journal:  Neuropharmacology       Date:  2013-02-13       Impact factor: 5.250

3.  Analgesic tolerance to morphine is regulated by PPARγ.

Authors:  Giordano de Guglielmo; Marsida Kallupi; Giulia Scuppa; Serena Stopponi; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 4.  PPARs and pain.

Authors:  Bright N Okine; Jessica C Gaspar; David P Finn
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

5.  Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.

Authors:  Ryan B Griggs; Renee R Donahue; Braxton G Adkins; Katie L Anderson; Olivier Thibault; Bradley K Taylor
Journal:  J Pain       Date:  2015-12-12       Impact factor: 5.820

6.  The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy.

Authors:  D F S Santos; R R Donahue; D E Laird; M C G Oliveira; B K Taylor
Journal:  Neuropharmacology       Date:  2021-11-29       Impact factor: 5.250

7.  The Cannabidiol Analog PECS-101 Prevents Chemotherapy-Induced Neuropathic Pain via PPARγ Receptors.

Authors:  Nicole Rodrigues Silva; Francisco Isaac Fernandes Gomes; Alexandre Hashimoto Pereira Lopes; Isadora Lopes Cortez; Jéssica Cristina Dos Santos; Conceição Elidianne Aníbal Silva; Raphael Mechoulam; Felipe Villela Gomes; Thiago Mattar Cunha; Francisco Silveira Guimarães
Journal:  Neurotherapeutics       Date:  2021-12-13       Impact factor: 6.088

8.  Effect of pioglitazone on neuropathic pain and spinal expression of TLR-4 and cytokines.

Authors:  Hongbin Jia; Shuangshuang Xu; Qingzhen Liu; Jian Liu; Jianguo Xu; Weiyan Li; Yi Jin; Qing Ji
Journal:  Exp Ther Med       Date:  2016-09-01       Impact factor: 2.447

9.  SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.

Authors:  Weina Ju; Qi Li; Sarah M Wilson; Joel M Brittain; Louay Meroueh; Rajesh Khanna
Journal:  Channels (Austin)       Date:  2013-03-19       Impact factor: 2.581

10.  Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPARγ mechanisms.

Authors:  Ryan B Griggs; Renee R Donahue; Jenny Morgenweck; Peter M Grace; Amanda Sutton; Linda R Watkins; Bradley K Taylor
Journal:  Pain       Date:  2015-03       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.